Organisation paid for research Program year 2025 Source: CMS Open Payments

Eastern Research Inc

Neither a doctor nor a teaching hospital

Research payments

$327,863

404 payments

Through program year 2025, Eastern Research Inc is reported as receiving $327,863 in research payments, across 404 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $77,444 165
2024 Research $27,325 5
2023 Research $38,178 65
2022 Research $140,364 112
2021 Research $22,887 56
2019 Research $21,665 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $187,761 366 payments
  2. Currax Pharmaceuticals LLC $71,305 1 payment
  3. Pfizer Inc. $27,750 10 payments
  4. Galderma Laboratories, L.P. $25,675 3 payments
  5. Genzyme Corporation $8,372 23 payments
  6. Purdue Pharma L.P. $7,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) $143,231 345 payments
  2. 17-AVP-825-301_Clinical Operations $71,305 1 payment
  3. Open-label 12-week Longitudinal Exploratory Study to Assess Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of PEDISTAD Patients $51,252 42 payments
  4. A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study of the Analgesic Efficacy and Safety of A Dose Titration Regimen for the Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $21,665 1 payment
  5. A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis $17,425 2 payments
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis $8,250 1 payment
  7. Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $7,000 1 payment
  8. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $2,411 6 payments
  9. An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $1,840 1 payment
  10. An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $1,834 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record